Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?
Open accessThe DOI matches its Crossref record; 265 of the 267 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Chronic inflammatory skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa are systemic conditions marked by persistent immune activation. Growing evidence links them to molecular and vascular ageing, including oxidative stress, endothelial dysfunction, and reduced expression of longevity-related proteins like Klotho and SIRT1. This narrative review examines how Th17- and Th2-driven inflammation contributes to systemic inflammageing. Key cytokines—IL-17, IL-23, IL-4, IL-13, and IL-31—promote endothelial damage, oxidative stress, and metabolic dysfunction. We highlight the role of vascular biomarkers (e.g., VCAM-1, ICAM-1, ST2, P-selectin) and immune cell senescence as indicators of ageing. Finally, we explore whether biologic therapies targeting these pathways may attenuate inflammation-driven ageing. Chronic skin diseases may thus serve as accessible models of systemic inflammageing and targets for early intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These features are not only diagnostically useful but also reflect disease-specific immune mechanisms that increasingly inform therapeutic targeting across inflammatory dermatoses [1,2,3,4,5].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“T lymphocytes play a central role in coordinating disease-specific immune responses, with distinct subtypes such as T helper 1 (Th1), T helper 2 (Th2), and T helper 17 (Th17) driving various inflammatory phenotypes.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The cutaneous immune microenvironment is predominantly driven by type 2 immune responses (mediated by Th2) with additional involvement of Th22 and Th1 pathways in chronic stages.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to circulating immune cells, tissue-resident memory T cells contribute to the persistence and recurrence of inflammation, emphasizing the importance of local immune regulation.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In atopic dermatitis, the most characteristic features are spongiosis, epidermal barrier disruption, and a superficial perivascular lymphocytic infiltrate.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [1]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–267 of 267
IL-4 Gene Polymorphism May Contribute to an Increased Risk of Atopic Dermatitis in Children
Shang, H., Cao, X.-L., Wan, Y.-J., Meng, J., & Guo, L.-H. (2016) · Disease Markers · doi:10.1155/2016/1021942 · Cited by 38 · cited 1×
“A study conducted by Hong Schang et al. demonstrated that the 590T and 589T alleles of the IL-4 gene may be associated with elevated serum IL-4 levels, potentially increasing the risk of atopic dermatitis development in children [84].”
Niknezhad, N., Haghighatkhah, H., Zargari, O., Ghalamkarpour, F., Younespour, S., Niknejad, N., Alikhan, A., & Abdollahimajd, F. (2020) · Dermatologic Therapy · doi:10.1111/dth.13628 · Cited by 38 · cited 1×
“A study conducted by Niknezhad N et al. demonstrated elevated hs-CRP levels in patients with psoriasis, suggesting that anti-inflammatory therapy, commonly used in chronic inflammatory diseases, could potentially reduce the risk of cardiovascular disease [224].”
Biologics for chronic inflammatory skin diseases: an update for the clinician
Yao, Y., Jørgensen, A. R., & Thomsen, S. F. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1589643 · Cited by 37
Can Blood-Circulating Factors Unveil and Delay Your Biological Aging?
Rybtsova, N., Berezina, T. N., Kagansky, A., & Александрович, Р. С. (2020) · Biomedicines · doi:10.3390/biomedicines8120615 · Cited by 36 · cited 2×
“Additionally, they may function as diagnostic markers for assessing cardiovascular risk in patients with chronic inflammatory diseases [43,226,227] With age and biological ageing, serum levels of VCAM-1 and ICAM-1 increase, a change associated with the process of inflammageing [220].”
Mikhaylov, D., Hashim, P. W., Nektalova, T., & Goldenberg, G. (2019) · PubMed · Cited by 35
Saviano, A., Mansour, A. A., Raucci, F., Merlino, F., Marigliano, N., Schettino, A., Wahid, M., Begum, J., Filer, A. D., Manning, J. E., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224479 · Cited by 34 · cited 1×
“Secukinumab and ixekizumab (anti-IL-17A antibodies), as well as bimekizumab (anti-IL-17A/F antibody), are effective drugs used in the biological therapy of psoriasis [229].”
Beck, L. A., Muraro, A. M., Boguniewicz, M., Chen, Z., Zahn, J., & Marco, A. R. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.08.005 · Cited by 34 · cited 1×
“This approach could lead to improved overall health and quality of life for patients, as well as reduce the risk of developing comorbidities and slow down biological ageing processes [187,201–204].”
Increased subclinical atherosclerosis in patients with chronic plaque psoriasis
Evensen, K., Slevolden, E., Skagen, K. R., Rønning, O. M., Brunborg, C., Krogstad, A., & Russell, D. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.008 · Cited by 31
Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis
Meng, Y., Li, D., Yanbin, P., Jinju, F., Meile, T., Lu, B., Xiao, H., Ping, T., & Jian-min, L. (2014) · Clinical and Experimental Dermatology · doi:10.1111/ced.12390 · Cited by 30 · cited 1×
“A key advantage is its convenient dosing regimen, allowing for administration every 12 weeks while maintaining sustained clinical effectiveness, a favourable safety profile and high patient tolerability [160,163,164].”
Li, Q., Ding, S., Wang, Y. M., Xu, X., Shen, Z., Fu, R., Liu, M., Hu, C., Zhang, C., Cao, Q., et al. (2017) · Europe PMC (PubMed Central) · Cited by 30
Risk of Venous Thromboembolism Among Adults With Atopic Dermatitis
Chen, T., Huang, W., Loh, C., Huang, H., & Chi, C. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.1300 · Cited by 30
Piros, É. A., Szabó, Á., Rencz, F., Brodszky, V., Szalai, K., Galajda, N. Á., Szilveszter, B., Dósa, E., Merkely, B. P., & Holló, P. (2021) · Life · doi:10.3390/life11090919 · Cited by 29 · cited 1×
“Patients with severe psoriasis have been shown to exhibit increased carotid IMT (cIMT) compared to healthy controls [243–245].”
Telomere Checkpoint in Development and Aging
Kalmykova, A. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115979 · Cited by 29 · cited 1×
“During cell division, telomeres shorten, and their critical shortening triggers a persistent DNA damage response that leads to cellular senescence through p53-dependent mechanisms or apoptosis [18,53].”
Lebwohl, M., Leonardi, C. L., Mehta, N. N., Gottlieb, A. B., Mendelsohn, A. M., Parno, J., Rozzo, S. J., & Menter, A. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.047 · Cited by 28 · cited 1×
“The long-term efficacy of tildrakizumab has been confirmed in patients with psoriasis both with and without coexisting metabolic syndrome [185,186].”
Could Inflammaging and Its Sequelae Be Prevented or Mitigated?
Man, M., & Elias, P. M. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s235595 · Cited by 27 · cited 3×
“…the skin, often coexists with cardiovascular diseases, atherosclerosis, metabolic syndrome, type 2 diabetes, obesity, psoriatic arthritis (PsA), inflammatory bowel disease, and non-alcoholic fatty liver disease (NAFLD), all of which occur more frequently than in the general population [210–212].”
Zinellu, A., & Mangoni, A. A. (2021) · Biomedicines · doi:10.3390/biomedicines9111707 · Cited by 27 · cited 2×
“…with ageing include IL-6, hs-CRP, VCAM-1, ICAM-1, and IL-17A [79,218–220] Additionally, evidence indicates a significant role for soluble selectins, such as sP-selectin, in endothelial dysfunction and the development of atherosclerosis, which may indirectly link them to cardiovascular ageing [46].”
Hong, J. J., Hadeler, E. K., Mosca, M., Brownstone, N. D., Bhutani, T., & Liao, W. J. (2022) · Journal of Psoriasis and Psoriatic Arthritis · doi:10.1177/24755303211047479 · Cited by 27 · cited 1×
“Currently, however, TNF-α inhibitors demonstrate lower therapeutic efficacy compared to newer, more selective IL-17 and IL-23 inhibitors, which is why they are increasingly being replaced in the treatment of chronic inflammatory skin diseases [191].”
SIRT1 as a Novel Potential Treatment Target for Vascular Aging and Age-Related Vascular Diseases
Wang, F., Chen, H., Lv, X., & Liu, D. (2012) · Current Molecular Medicine · doi:10.2174/156652413804486223 · Cited by 27
The Role of Sirtuins in the Pathogenesis of Psoriasis
Słuczanowska-Głąbowska, S., Salmanowicz, M., Staniszewska, M., & Pawlik, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310782 · Cited by 27
Expression of sirtuins 1, 6, tumor necrosis factor, and interferon-γ in psoriatic patients
Rasheed, H., El-Komy, M. H. M., Hegazy, R., Gawdat, H., AlOrbani, A. M., & Shaker, O. G. (2016) · International Journal of Immunopathology and Pharmacology · doi:10.1177/0394632016662475 · Cited by 26 · cited 2×
“In the future, SIRT1 activators may represent a novel, targeted therapeutic strategy for chronic inflammatory skin diseases, potentially preventing skin ageing and slowing vascular ageing [252,256,257].”
Diels, J., Thilakarathne, P. J., Cameron, C. G., McElligott, S. C., Schubert, A., & Puig, L. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18634 · Cited by 26 · cited 2×
“Currently, however, biological drugs that specifically block the p19 subunit of IL-23, such as guselkumab, risankizumab and tildrakizumab, enable a more precise therapeutic approach thanks to their selective mechanism of action [6,165–167].”
The impact of dupilumab on skin barrier function: A systematic review
Montero‐Vílchez, T., la Torre, R. S.-D., Sánchez‐Díaz, M., Ureña‐Paniego, C., Molina‐Leyva, A., & Arias‐Santiago, S. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19081 · Cited by 26
Guselkumab for the treatment of adults with moderate to severe plaque psoriasis
Puig, L. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1601014 · Cited by 24
Shen, C., Lu, C., Wu, C.-H., Li, K., Kuo, Y., Hsieh, S., & Yu, C. (2021) · Cells · doi:10.3390/cells10123402 · Cited by 24 · cited 3×
“This condition contributes to sustained activation of immune cells and represents one of the most important mechanisms underlying inflammageing and accelerated biological ageing [64,76].”
Fernandez, A. P., Daudén, E., Gerdes, S., Lebwohl, M., Menter, A., Leonardi, C., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J. ‐., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18167 · Cited by 24 · cited 1×
“The long-term efficacy of tildrakizumab has been confirmed in patients with psoriasis both with and without coexisting metabolic syndrome [185,186].”
IL-17A induces valvular endothelial inflammation and aggravates calcific aortic valve disease
Yang, Z., Zhang, J., Zhu, Y., Zhang, C., Li, G., Liu, S., Du, J., Han, Y., & You, B. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.079 · Cited by 24 · cited 1×
“IL-17 is a key mediator of sustained chronic inflammation, especially in immune-mediated diseases such as psoriasis (Figure 3) [32,69,74,75].”
Plasma levels of sirtuin-1 in patients with cerebrovascular stroke
Esmayel, I. M., Hussein, S., Gohar, E. A., Ebian, H. F., & Mousa, M. M. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05074-9 · Cited by 23 · cited 1×
“Klotho and SIRT1 proteins can also be measured using the ELISA method [58].”
Shakoei, S., Nakhjavani, M., Mirmiranpoor, H., Motlagh, M. A., Azizpour, A., & Abedini, R. (2021) · PubMed · Cited by 23
Bellinato, F., Chiricozzi, A., Piaserico, S., Targher, G., & Gisondi, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112849 · Cited by 23 · cited 1×
“Targeted pharmacotherapy can therefore modify the course of chronic inflammatory skin diseases by normalising gene expression and the phenotype of immune cells [263].”
Li, N., Luo, R., Zhang, W., Wu, Y., Hu, C., Liu, M., Jiang, D., Jiang, Z., Zhao, X., Wang, Y., et al. (2022) · Biogerontology · doi:10.1007/s10522-022-09999-2 · Cited by 22 · cited 5×
“These processes contribute to endotheliopathy, vascular damage, and accelerated atherosclerosis [18,79,80].”
InfluentialOxidative stress and metabolic biomarkers in patients with Psoriasis
Bakić, M., Klisic, A. N., Kocic, G. M., Kocić, H., & Karanikolić, V. (2023) · Journal of Medical Biochemistry · doi:10.5937/jomb0-45076 · Cited by 22 · cited 1×
“This disrupted redox balance contributes to increased IL-17 production [234,235].”
Kwiek, B., Narbutt, J., Sysa‐Jędrzejowska, A., Langner, A., & Lesiak, A. (2017) · Advances in Dermatology and Allergology · doi:10.5114/ada.2017.67077 · Cited by 20 · cited 2×
“Therefore, P-selectin levels may potentially serve as a biomarker for assessing treatment efficacy in these conditions [230,232].”
Fotopoulou, F., Rodriguez-Correa, E., Dussiau, C., & Milsom, M. D. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104698 · Cited by 19 · cited 2×
“With age, their numbers increase, but their functionality gradually declines, resulting in a loss of self-renewal and regenerative capacity [9,11,12].”
The relationship between biological aging and psoriasis: evidence from three observational studies
Lin, Z., Wang, H., Yu, L.-Y., Chen, J., Kong, C., Zhang, B., Wu, X. R., Wang, H., Cao, Y., & Lin, P. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00500-4 · Cited by 19
Egeberg, A., Jullien, D., du Jardin, K. G., & Thaçi, D. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2220447 · Cited by 17 · cited 1×
“Its therapeutic effect, good safety profile, and positive impact on improving patients’ health-related quality of life (HRQoL) have been well documented in clinical trials [181–184].”
Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
Gordon, K. B. (2010) · Core evidence · doi:10.2147/ce.s5994 · Cited by 16 · cited 1×
“It was approved by the U.S. Food and Drug Administration (FDA) in 2009 for the treatment of moderate to severe psoriasis [135,160–162].”
Soluble P-selectin is the smoke, not the fire
Gross, P. L. (2017) · Blood · doi:10.1182/blood-2017-05-786319 · Cited by 16 · cited 1×
“P-selectin levels are elevated in vascular inflammatory conditions such as atherosclerosis, myocardial infarction, hypertension, and venous thrombosis, which makes it a potential marker for assessing the risk of these disorders [48].”
Zdanowska, N., Owczarczyk-Saczonek, A. B., Czerwińśka, J., Nowakowski, J. J., Kozera‐Żywczyk, A., Owczarek, W. D., Zdanowski, W., & Placek, W. J. (2020) · Medicina · doi:10.3390/medicina56090473 · Cited by 16 · cited 2×
“Biological therapies, including TNF-α inhibitors, may exert a positive effect by improving endothelial cell function [228,247].”
Microplate ELISAs for soluble VCAM-1 and ICAM-1.
Chang, P.-Y., Wu, T., Tsao, K., Li, C.-C., Sun, C., & Wu, J. T. (2005) · PubMed · Cited by 15
Genre, F., Armesto, S., Corrales, A., López‐Mejías, R., Remuzgo‐Martínez, S., Pina, T., Ubilla, B., Mijares, V., Martín-Varillas, J. L., Rueda‐Gotor, J., et al. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1329498 · Cited by 15 · cited 1×
“Its blood levels increase during vascular endothelial inflammation and platelet activation, making it a biomarker of both processes [46,47].”
Association Between the Anti-Aging Gene Klotho and Selected Rheumatologic Autoimmune Diseases
Russell, D. L., Oates, J. C., & Markiewicz, M. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.10.021 · Cited by 15 · cited 1×
“Both Klotho expression and circulating concentrations decline with age, and this reduction may serve as an early marker of premature vascular ageing and atherosclerosis [258–261].”
The Role and Implications of Epidermal Dysfunction in the Pathogenesis of Inflammaging
Zhang, J., Xia, B., Wakefield, J. S., Elias, P. M., & Wang, X. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.09.025 · Cited by 14 · cited 1×
“These mechanisms represent a key factor in the development of in-flammageing and its associated consequences, including the accelerated progression of age-related diseases [60,198,264].”
Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis
Chang, J., Huang, X., Jiang, W., Lun, L., Liu, W., Xu, R., Tang, R., Xie, X., Zhai, W., Su, H., et al. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.04.027 · Cited by 14 · cited 1×
“These components are essential for preserving the integrity of the skin barrier [35,36,107].”
Wu, J. J., Amand, C., No, D. J., Mahajan, P. S., Gadkari, A. S., Ghorayeb, E., Kaur, M., Korotzer, A. R., & Eckert, L. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00587-9 · Cited by 13
Çelik, M. S., & Aktaş, H. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-03969-6 · Cited by 13
A systematic review on the efficacy and safety of Infliximab in patients with psoriasis
Wang, J., Zhan, Q., & Zhang, L. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1081322 · Cited by 12
Wen, Z., Liu, X., & Zhang, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-64050-3 · Cited by 12
Anti-Inflammatory Role of the Klotho Protein and Relevance to AgingPreprint
Prud’homme, G. J., & Wang, Q. (2024) · Preprints.org · doi:10.20944/preprints202408.0213.v1 · Cited by 12
Bissonnette, R., Goleva, E., Berdyshev, E. V., Garcia, S. L., Ramirez-Gama, M. A., Taylor, P. A., Bologna, G., Praestgaard, A. H., Chen, L., Levit, N. A., et al. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.11.079 · Cited by 12
Molina‐Leyva, A., Husein‐ElAhmed, H., Naranjo‐Sintes, R., & Ruiz‐Carrascosa, J. C. (2014) · PubMed · Cited by 11
Jiang, W., Li, Q., & Zheng, W. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-04174-2 · Cited by 11 · cited 1×
“Dysregulation of the Th17-dependent immune response is associated not only with chronic skin inflammation but also with comorbidities such as cardiovascular disease and metabolic syndrome [156,157].”
Sun, Y., Liu, H., Gao, Y., Sang, H., & Kong, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1587977 · Cited by 11
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
Sekhon, S., Jeon, C., Nakamura, M., Yan, D., Afifi, L., Bhutani, T., & Levin, E. C. (2017) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s129792 · Cited by 9 · cited 1×
“Its efficacy and safety in treating patients with moderate to severe plaque psoriasis or active psoriatic arthritis, particularly those who have had inadequate response to prior tumour necrosis factor inhibitor therapy, have been confirmed in clinical trials [135,144–149].”
Nomura, S. (2003) · PubMed · Cited by 8
Carrascosa, J. M., Rebollo, F. J., Gómez, S., & de la Cueva, P. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1467536 · Cited by 8 · cited 1×
“They are effective and well tolerated, providing symptom relief, improved skin condition, and enhanced quality of life in patients with psoriasis [39,135,187–189].”
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience
Becatti, M., Urban, M. L., Taurisano, G., Mannucci, A., Barygina, V. V., Pescitelli, L., Prignano, F., Silvestri, E., Taddei, N., Lotti, T., et al. (2018) · Dermatologic Therapy · doi:10.1111/dth.12675 · Cited by 8 · cited 1×
“Reductions in oxidative stress and enhanced total antioxidant capacity were also observed in patients treated with secukinumab [241].”
Bhatia, N. D., Heim, J., Vasquez, J. G., Bhutani, T., Schenkel, B., Gogineni, R., & Koo, J. Y. M. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2310631 · Cited by 8 · cited 2×
“Its therapeutic effect, good safety profile, and positive impact on improving patients’ health-related quality of life (HRQoL) have been well documented in clinical trials [181–184].”
Heim, J., Vasquez, J. G., Bhutani, T., Koo, J. Y. M., Mathew, J., Gogineni, R., Ferro, T. J., & Bhatia, N. D. (2024) · Journal of Drugs in Dermatology · doi:10.36849/jdd.8217 · Cited by 8
Mechanistic role of RND3-regulated IL33/ST2 signaling on cardiomyocyte senescence
Wu, L., Zhu, X., Luo, C., Zhao, Y., Pan, S.-S., Shi, K., Chen, Y., Qiu, J., Shen, Z., Guo, J., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122701 · Cited by 7
SIMONE, C. D., Caldarola, G., Coco, V., Palumbo, S., Pocino, K., Sgambato, A., Maiorino, A., Corbi, M., Sandri, M. T., Vendittelli, F., et al. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12140 · Cited by 6 · cited 1×
“The reduction in CEC levels following therapy confirms that targeted biological treatment can improve endothelial function, reducing the risk of complications arising from its dysfunction [248].”
Timiș, T. L., Florian, I. A., Vesa, Ș. C., Beni, L., & Orăsan, M. S. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070457 · Cited by 5 · cited 1×
“These findings confirm that targeted cytokine blockade can effectively reduce chronic inflammation, leading to clinical improvement in patients [207].”
High-Sensitivity CRP and Occurrence of Cancer in Cardiovascular Disease Patients with Cardiovascular
Bonardeaux, O. D. L. B., Deneye, M., Oury, C., Moonen, M. L., & Lancellotti, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041193 · Cited by 5 · cited 2×
“Studies have shown an association between hsCRP levels and the presence of cardio-vascular diseases and atherosclerosis, which is why it is considered a potential indicator or predictor of disease occurrence [50,51].”
Effects of Different Therapeutic Approaches on Redox Balance in Psoriatic Patients
Medovic, M. V., Milicic, V. M., Ravić‐Nikolić, A., Ristić, G., Medović, R., Nikolic, M. R., Stojanović, A., Bolevich, S., Bondarchuk, N. G., Gorbunov, A. A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12030587 · Cited by 4 · cited 1×
“Biological drugs, such as IL-17A, IL-12/23, and TNF-α inhibitors, used in the treatment of chronic inflammatory dermatoses, exhibit potential antioxidant effects by reducing oxidative stress, limiting persistent inflammation driven by free radicals, and modulating the immune response [236,239–242].”
Errichetti, E., Wolf, P., Khattri, S., Gorecki, P. C., Miller, M., Jiang, J., Han, C., & Kirby, B. (2024) · Acta Dermato Venereologica · doi:10.2340/actadv.v104.41053 · Cited by 4 · cited 1×
“…residual psoriasis lesions during ustekinumab therapy who switched to guselkumab showed improvements in skin clearance and quality of life [166–168 Early initiation of guselkumab therapy after psoriasis diagnosis may contribute to achieving a better clinical response and a faster…”
Gottlieb, A. B., Armstrong, A. W., Blauvelt, A., Griffiths, C. E. M., Pinter, A., Gooderham, M., Lomaga, M. A., Burge, R. T., Konicek, B. W., McDonald, M. F., et al. (2024) · Journal of Drugs in Dermatology · doi:10.36849/jdd.8160 · Cited by 2
Effects of Adalimumab on Mitochondria of Psoriatic Mesenchymal Stem Cells
Vincenzo, M. D., Campanati, A., Cannelonga, G., Diotallevi, F., Cerqueni, G., Marani, A., Marchi, S., & Orciani, M. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70642 · Cited by 2 · cited 2×
“However, adalimumab did not prevent mitochondrial dysfunction under conditions of additional oxidative or inflammatory stress, which could lead to symptom recurrence after treatment [249].”
Nomura, S. (2007) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.18.597 · cited 1×
“These activated particles can contribute to the development of atherosclerosis [49].”
Cited by
Skin aging: Mechanistic insights and targeted therapeutic strategies
Beaziz, J., Avallone, G., Langer, K., DUCA, E. D., Navrazhina, K., He, H., & Guttman‐Yassky, E. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.05.015 · Cited by 3
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1
Wang, K., & Zhang, J. (2026) · Journal of Science Advanced Materials and Devices · doi:10.1016/j.jsamd.2026.101177 · Cited by 1
Glucagon-like peptide-1 receptor agonists as metabolic adjuncts in immune-mediated skin disease
Lazarowitz, R., Saroufim, L., Sauder, M. B., Osman, M. S., Tardio, V., Litvinov, I. V., & Netchiporouk, E. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.02.047
Kim, T.-H., Shin, S., & Park, W. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00809-2
“Importantly, as the disease becomes chronic, the structural deformation of tissues becomes accompanied by inflammation (Andrzejczak et al. 2025).”
Metadata
- Authors
- Andrzejczak, K., Sternak, A., Witkowski, W., & Ponikowska, M.
- Affiliations
- Wroclaw Medical University (PL)
- Corresponding author
- Ponikowska, Małgorzata
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2025-09-15
- Volume
- 14
- Issue
- 18
- Pages
- 1442
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC12469205
- OpenAlex
- W4414206127
- Semantic Scholar
- 77db497849c105e7ce9941bcc0c7f75dfe8f5147
- Cited by
- 10
- References
- 265
- Citations by year
- 2026: 10
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wroclaw Medical University
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Skin Protection and Aging
- Keywords
- inflammaging, chronic inflammatory skin disease, atopic dermatitis, psoriasis, hidradenitis suppurativa, Th17 cells, Th2 cells, IL-17, IL-23, IL-4, IL-13, IL-31, oxidative stress, endothelial dysfunction, Klotho, SIRT1, vascular biomarkers, VCAM-1, ICAM-1, ST2, P-selectin, biologic therapy, systemic inflammation
- MeSH terms
- Aging, Animals, Biological Therapy, Chronic Disease, Humans, Inflammation, Skin Diseases, Cytokines, Cellular Senescence, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


